Evidence map›Paper›PMID 41839294›Full record

ArticleMucosal immunology2026

CD39 regulates P2RX7-mediated lung necrotic lesions in severe experimental tuberculosis.

Gislane Almeida-Santos, Igor Santiago-Carvalho, Fabrício Moreira Almeida, Caio César Barbosa Bomfim, Juan Carlo Santos E Silva, Deborah Giovanna Cantarini, Camila Ramos Silva, Martha Simões Ribeiro, Rogério Silva do Nascimento, Bruna de Gois Macedo and 9 more

Abstract read
In one paragraph

Article in Mucosal immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Gislane Almeida-SantosUniversidade de São Paulo (USP), Instituto de Ciências Biomédicas (ICB), Departamento de Imunologia, São Paulo, Brazil; University of Virginia School of Medicine, Charlottesville, VA, USA. Electronic address: yqv6ae@virginia.edu.
Igor Santiago-CarvalhoUniversidade de São Paulo (USP), Instituto de Ciências Biomédicas (ICB), Departamento de Imunologia, São Paulo, Brazil; Department of Immunology, Mayo Clinic, Scottsdale, AZ, USA.
Fabrício Moreira AlmeidaLaboratório de Biologia do Reconhecer, State University of North Norte Fluminense Darcy Ribeiro, Campos dos Goytacazes, Rio de Janeiro, Brazil.
Caio César Barbosa BomfimUniversidade de São Paulo (USP), Instituto de Ciências Biomédicas (ICB), Departamento de Imunologia, São Paulo, Brazil; Institute of Pharmacology and Structural Biology (IPBS), University of Toulouse, CNRS, Toulouse, France.
Juan Carlo Santos E SilvaUSP, Faculdade de Ciências Farmacêuticas (FCF), Departamento de Análises Clínicas e Toxicológicas, São Paulo, Brazil.
Deborah Giovanna CantariniUniversidade de São Paulo (USP), Instituto de Ciências Biomédicas (ICB), Departamento de Imunologia, São Paulo, Brazil.
Camila Ramos SilvaInstituto de Pesquisas Energéticas e Nucleares (IPEN), Brazil.
Martha Simões RibeiroInstituto de Pesquisas Energéticas e Nucleares (IPEN), Brazil.
Rogério Silva do NascimentoUniversidade de São Paulo (USP), Instituto de Ciências Biomédicas (ICB), Departamento de Imunologia, São Paulo, Brazil.
Bruna de Gois MacedoUniversidade de São Paulo (USP), Instituto de Ciências Biomédicas (ICB), Departamento de Imunologia, São Paulo, Brazil; Department of Immunology, Mayo Clinic, Scottsdale, AZ, USA.
Paulo Henrique Lisboa RaederUniversidade de São Paulo (USP), Instituto de Ciências Biomédicas (ICB), Departamento de Imunologia, São Paulo, Brazil.
Joaquim Teixeira-Xavier JuniorUniversidade de São Paulo (USP), Instituto de Ciências Biomédicas (ICB), Departamento de Imunologia, São Paulo, Brazil.
José Maria AlvarezUniversidade de São Paulo (USP), Instituto de Ciências Biomédicas (ICB), Departamento de Imunologia, São Paulo, Brazil.
Mario Hiroyuki HirataUSP, Faculdade de Ciências Farmacêuticas (FCF), Departamento de Análises Clínicas e Toxicológicas, São Paulo, Brazil.
Robson Coutinho-SilvaInstituto de Biofísica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
Simon C RobsonHarvard Medical School, Boston, MA, USA; Beth Israel Deaconess Medical Center, Boston, MA, USA.
Eduardo Pinheiro AmaralInflammation and Innate Immunity Unit, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Elena LasunskaiaLaboratório de Biologia do Reconhecer, State University of North Norte Fluminense Darcy Ribeiro, Campos dos Goytacazes, Rio de Janeiro, Brazil.
Maria Regina D'Império LimaUniversidade de São Paulo (USP), Instituto de Ciências Biomédicas (ICB), Departamento de Imunologia, São Paulo, Brazil. Electronic address: relima@usp.br.

Funding

Innate inflammatory responses during pulmonary infectionsZIAAI001207 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI MAYER-BARBER, KATRIN · 2015 to 2025
$13.6M
Intramural NIH HHS Z99 AI999999Intramural NIH HHS ZIA AI001207
6 · The paper itself

Abstract

Infection with Mycobacterium tuberculosis can cause diverse lesions, such as necrotic pneumonia, which can contribute to tuberculosis progression and transmission between individuals. Despite advances in understanding the role of ATP-gated P2RX7 ion channels in the development of severe forms of the disease, the regulation of this important signaling pathway remains unclear. Herein, we show that the ectonucleotidase CD39 plays an essential regulatory role in tuberculosis progression by preventing lung tissue damage, bacterial dissemination, and excessive inflammatory responses. Mechanistically, through its enzymatic activity on the cellular surface, CD39 protects infected macrophages from undergoing necrotic death mediated by P2RX7 activation. Cell-intrinsic CD39 expression also hinders the establishment of other myeloid cells, such as neutrophils, in the infected lung. We proposed that, by protecting infected macrophages from P2RX7-mediated cell death and bacterial dissemination in the lung tissue, CD39 prevents the development of necrotic lesions. Altogether, these findings uncover a significant role for CD39 as an essential component of the molecular regulation underlying the development of severe tuberculosis.

Indexed as

Antigens, CDApyraseLungMacrophagesMycobacterium tuberculosisReceptors, Purinergic P2X7TuberculosisTuberculosis, PulmonaryAnimalsCells, CulturedDisease Models, AnimalHumansMiceMice, Inbred C57BLMice, KnockoutNecrosisAntigens, CDApyraseCD39 antigenP2rx7 protein, mouseReceptors, Purinergic P2X7CD39MacrophagesNecrotic pneumoniaP2RX7Tuberculosis

Identifiers

PMID41839294
PMCPMC13148415

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.